ripheral blood monocytes in monolayers (55) and adherent or suspended alveolar macrophages (56, 57) respond to the ionophore with a substantial generation ofLTB4 and, for the former, ofLTC4; alveolar macrophages generate LTB4 in amounts ranging from 100 to 400 ng/106 cells and in an average 20-fold excess, relative to LTC4. Thus, depending upon the cell type in an inflammatory focus, the potential leukotriene production can be predominantly LTB4, with implications for endothelial cell adherence and chemotaxis of additional cells (9, 10, 32) , or LTC4, with marked arteriolar constrictive and venular permeability-augmenting effects (7, 31, 32, 36, 43) . Implications about the role of a cell, which are drawn from profiles of products obtained with ionophore activation, must be tempered by the limited data available for cells in response to transmembrane physiologic stimuli. In the case of monocyte monolayers responding to unopsonized zymosan (55) , the quantities of leukotriene products are reduced to one-third or less of those elaborated by the calcium ionophore. Similarly, murine bone marrow-derived mast cells, differentiated in vitro and presumed to be mucosal-type mast cells, elaborate 20-50 ng LTC4 and 4-8 ng LTB4/106 cells after IgE-dependent activation, or less than one-half of the leukotrienes obtained from the same cells activated with calcium ionophore (58) (59) (60) . These murine mast cells generate almost no prostaglandin D2, whereas that is the predominant product of oxidative metabolism of arachidonic acid by rat and human connective tissue mast cells activated by an immunologic mechanism (61) .
The definitions ofthe various enzymes in the 5-lipoxygenase cascade ( Fig. 1 ) are mainly based upon the knowledge of their respective substrates and products, and to a much lesser degree upon biochemical parameters. No mammalian enzyme in the 5-lipoxygenase pathway has been purified to homogeneity in a functional state. The 5-lipoxygenase converts arachidonic acid (5,8,11,14- eicosatetraenoic acid) to 5S-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-HPETE) (62). 5-lipoxygenase is a calcium-dependent cytosolic enzyme in cell-free preparations from RBL-1 rat basophilic leukemia cells, guinea pig PMN, and human PMN (63) (64) (65) , and in the RBL-l preparations it is considered to manifest catalytic activity only as a calcium-dependent dimer (63) . After extraction from guinea pig PMN, its preferential substrates are arachidonic acid and (5,8,11,14,17-cis)-eicosapentaenoic acid, which is preferentially present in fish fatty acid-enriched diets, but not such common fatty acids as linoleic (9,12-cis-octadecadienoic acid) and linolenic (9,12,15-cis-octadecatrienoic acid), which lack a 5,6-olefinic bond (64 5-HPETE is converted by a dehydrase to 5,6-trans-oxido-7,9-trans-1 1, 14-cis-eicosatetraenoic acid, (leukotriene A4, LTA4) (66) or is hydrolyzed to its alcohol, 5S-hydroxy-6-trans-8, 11,14-cis-eicosatetraenoic acid. Nonenzymatic hydrolysis of LTA4 generates the biologically inactive isomers of LTB4, 5S, 12R-and 5S, 12S-dihydroxy-6,8, I 0-trans-14-cis-eicosatetraenoic acid (6-trans-LTB4 diastereoisomers) along with small quantities of 5,6-dihydroxy-eicosatetraenoic acids (66) . From LTA4, an epoxide hydrolyase generates LTB4, and a glutathione-S-transferase adducts glutathione to form LTC4. The cytosolic epoxide hydrolase ofthe RBL-1, a cell that generates the biologically active leukotrienes, is biochemically uncharacterized (67) . Rat liver has both cytosolic and microsomal epoxide hydrolases, which differ in antigenic determinants, pH optima, and substrate specificity (68, 69) . One of these converts various cis-epoxides of arachidonic acid to diols (70) but has not been assessed for activity on trans-epoxides such as LTA4. The LTA4-glutathione-S-transferase of the RBL-1, which generates LTC4, is associated with a 10,000 g particulate fraction after cell disruption (71) . Rat liver cytosolic and microsomal glutathione-S-transferases have been shown to be both biochemically and antigenically distinct from each other, and the microsomal enzyme requires preincubation with N-ethylmaleimide to achieve maximal catalytic activity (72) . Of the purified glutathione-S-transferases, only the E and g-type cytosolic isoenzymes from rat and human liver, respectively, demonstrate the capacity to utilize a nonleukotriene epoxide substrate (72, 73) to form a glutathione adduct.
The biosynthetic events leading to the generation of LTC4 and LTB4 are generally entirely intracellular. An LTA4 epoxide hydrolase has been demonstrated as an extracellular enzyme in blood plasma (74) but the physiological significance is undetermined and would depend upon the extracellular generation or release of LTA4. In contrast, y-glutamyl transpeptidases and dipeptidases, which convert LTC4 to LTD4 (75, 76) and chloride ion to form hypochlorous acid (HOCI) (20, 21). The latter compound generates a chlorosulfonium ion intermediate from each sulfidopeptide leukotriene, and subsequently, the biologically inactive 6-trans-LTB4 diastereoisomers and the substrate-specific S-diastereoisomeric sulfoxides of LTC4, LTD4, and LTE4 (Fig. 2) . In view of the spasmogenic activity of the synthetic sulfones (80), these compounds have been sought but not found during the oxidative inactivation of the sulfidopeptide leukotrienes (21) . The initial observations that eosinophils from hypereosinophilic donors spontaneously inactivated SRS-A, whereas peripheral blood neutrophils and monocytes from normal donors did not (81) , is now explicable by the finding that such "activated" eosinophils spontaneously convert LTC4 to the 6-trans-LTB4 diastereoisomers and the S-diastereoisomeric LTC4 sulfoxides through the generation of HOCI (54) . The inactivation of SRS-A by eosinophil arylsulfatase B (82), and arylsulfatase A and B of other cell types ( 15, 83) is now attributed to their contamination with dipeptidases, which converted LTD4 to the less spasmogenic LTE4, as assessed on the guinea pig ileum. Whereas the catabolism of the sulfidopeptide leukotrienes by endogenously or experimentally activated neutrophils and eosinophils is extracellular and completely curtailed in the presence of a scavenger of HOCI, such as L-serine (20, 21, 54), the inactivation of LTB4 is intracellular in neutrophils (19) and is not observed with eosinophils or peripheral blood monocytes in adherent monolayers (54, 55) . The neutrophil-dependent intracellular inactivation of LTB4 occurs by w-oxidation (19) and is not augmented by activation with the calcium ionophore.
Receptors and secondary factors in the integrated response to leukotrienes. The evidence for cellular receptors for LTB4 and for the sulfidopeptide leukotrienes is derived from studies of structure-function correlations and radioligand binding. For LTB4, the specificity of its interaction with human PMN was first suggested by its 30-to 300-fold greater chemotactic potency as compared with naturally occurring isomers (10, 11), 1 2-epi-6-trans-8-cis-LTB4, derived by sequential 5-and 1 2-lipoxygenation of arachidonic acid (84) , and 5S, 12S-and SS, 12R-6-trans-LTB4. Saturation binding of [3HJLTB4 to human PMN has been presented as additional evidence for the existence of specific receptors (85, 86) . In one study, the dissociation constant (Kd) for the ligand was 1 sites per cell was 26,000-40,000 (85) . In the other study, the Kd was 270 nM with 386,000 specific binding sites per cell and the binding at 40C was irreversible (86) . The criteria for a stereospecific receptor for LTB4 on human PMN are not yet adequately delineated. The structural determinants of LTC4 and LTD4 spasmogenic functions on nonvascular smooth muscle have been shown to exist in the presence of the hydrophobic omega region and in the spatial relationships of the polar region. Although the precise stereochemistry of the omega region is not essential for modest nonvascular smooth muscle contractile activity, as indicated by potencies ofthe 14,15-dihydro and 9,10,11,12,14,15-hexahydro analogues of both LTC4 and LTD4 (24) , the region cannot be deleted. C-9, C-12, and C-14-apo-LTD4, respectively lacking 9, 12, and 14 carbons, are completely inactive as spasmogens, indicating a possible binding function for the hydrophobic omega region (26) as a requisite for receptor activation by the stereochemically appropriate polar region. Stereochemical requirements for spasmogenic activity on the guinea pig ileum and guinea pig pulmonary parenchymal strip have been identified by use of synthetic chiral isomers at the three optically active centers in the natural sulfidopeptide leukotrienes: carbon 5 (C-5) of the eicosanoid backbone, which bears the hydroxyl; C-6, to which is conjugated the sulfidopeptide; and the asymmetric carbon ofcysteine in the sulfidopeptide adduct. Diastereoisomers at C-5 and C-6 of LTD4 and that at C-6 of LTC4 each exhibit <0.5% of the nonvascular smooth muscle spasmogenic activity of the corresponding naturally occurring leukotriene (25, 26). Substitution of D-cysteine for L-cysteine in LTD4 causes only a modest decrement in potency, and replacement of the glycine of LTD4 by )-or L-alanine is relatively inconsequential in effect (25, 26) . Thus, the rigorous relationships of function to the stereochemistry of the C-5 and C-6 polar adducts to the eicosanoid backbone are not expressed more distally in the sulfidopeptide chain, indicating that the critical spatial arrangements exist between the eicosanoid carboxyl and the polar adducts, as would be the case for true receptors.
Initial functional evidence for heterogeneity of sulfidopeptide leukotriene receptors is provided by the markedly different molar ratios of the concentrations of LTC4/LTD4/LTE4 required for elicitation of identical biologic effects in different tissues (7, 87) , by the biphasic dose-response isometric contraction of guinea pig lung parenchymal strips to LTD4 but not LTC4, and by the capacity of FPL55712 to competitively inhibit only the lowdose phase of the LTD4-mediated contraction (31) . The putative high affinity receptor mediating a LTD4 response that is competitively inhibited by FPL55712 is tentatively designated LT-RI, whereas the lesser affinity receptor, apparently responding to LTC4 and high concentrations of LTD4, has been designated LT-R2. This interpretation is supported by the finding that a calcium channel blocker (diltiazem) inhibits the high-dose LTD4 contraction presumably via LT-R2 and allows FPL55712 to give dose-related inhibition of a full LTD4 dose-response via LT-RI (88 (91) or acetylsalicylic acid (92) has been reported to attenuate their response to limited, but defined, concentrations ofLTC4 or LTD4. However, a very detailed concentration-effect curve analysis of the contractile response of guinea pig pulmonary parenchymal strips to synthetic LTB4, LTC4, LTD4, and LTE4, in the presence and absence of different concentrations ofindomethacin and the thromboxane synthetase inhibitor, clotrimazole, revealed cyclooxygenase products to mediate the LTB4 effect, while being of minor importance to the contractions induced by the sulfidopeptide leukotrienes (93) .
Pharmacologic actions. The sulfidopeptide leukotrienes LTC4 and LTD4 evoke preferential bronchospastic responses by peripheral airways vs. central airways after intravenous infusion in guinea pigs and after administration as aerosols to both guinea pigs and humans (31, 34, 40, 41, 94 ). It is not presently possible to ascribe the preference of a sulfidopeptide leukotriene for compromise ofsmall as compared with large airways to a specific biologic effect on smooth muscle, microvasculature, and/or mucus-secreting cells (95, 96) , and more than one target tissue may be involved.
It is particularly intriguing to speculate that the sulfidopeptide leukotrienes may be critical to the clinical problem ofbronchial asthma, a condition marked by "hyperirritability" of the airways as defined by impaired pulmonary function in response to inhalation ofpharmacologic agonists and irritants at concentrations that are inactive in normal individuals (97, 98) . When asymptomatic asthmatic subjects with a demonstrated hyperreactivity to inhaled histamine received LTD4 by aerosol, the average concentration evoking a 30% decrement in maximal midexpiratory airflow, measured at 30% of vital capacity (V30), was similar to that having a comparable action in normal subjects (41, 42) . The molar potency of LTD4 relative to histamine was 2 logs greater in asthmatic subjects and 3.5 logs greater in normal persons (41, 42) . Because hyperresponsiveness to LTD4 inhalation was not observed in the asthmatic subjects, LTD4 may act at a site distinct from that of other agonists and irritants to compromise air flow, and may, in addition, effect the nonspecific airway hyperresponsiveness. In view of the recent delineation of at least two distinct sulfidopeptide leukotriene receptors (27, 28, 30) , it is possible that one receptor accounts for the airway "hyperirritability" and another for the direct leukotriene-mediated component of bronchoconstriction.
In addition to their actions on nonvascular smooth muscle, LTC4 and LTD4 effect arteriolar constriction. This action was originally observed by injecting guinea pigs intradermally with 10-100 pmol of LTC4 and LTD4 and infusing sufficient Coomassie Blue dye to pigment all areas of the skin except for those pretreated with the leukotrienes (31) . Subsequently, direct visualization of blood flow in the hamster cheek pouch, using intravascular fluorescein, allowed photomicrographic documentation of the vasoconstrictor response to LTC4 and LTD4 after each had been separately applied topically to the buccal mucosa (32) .
A separate vascular effect mediated by the sulfidopeptide leukotrienes, that of augmented vasopermeability in response to LTC4, LTD4, or LTE4, was also observed in guinea pig skin (7, 31) , hamster buccal mucosa (32) , and human skin (43) . Human subjects injected intradermally with 1 nmol of LTC4, LTD4, and LTE4 developed a local wheal at each site, which lasted >2 h, and an erythematous flare persisting 6-8 h (43) . The combined vascular effects ofthe sulfidopeptide leukotrienes have been recognized in rats subjected to a 5-min intravenous infusion of LTC4. Increased total peripheral resistance, coronary resistance, and renovascular resistance occurred during the infusion as immediate and direct responses, and augmented venopermeability with depletion of plasma volume appeared as a subsequent response. The combined effects decreased cardiac output, renal blood flow, and glomerular filtration rate, long after the LTC4 infusion had been completed (36).
The in vivo actions of LTB4, after intradermal injection in the rhesus monkey ( 11) and humans (43) , promote neutrophil infiltration of the local tissue sites as assessed by biopsies. In the human subjects, this response was also recognized by induration and tenderness at the site, most prominent 4-6 h after injection (43) . That the movement of neutrophils into tissues in response to LTB4 follows their margination was demonstrated by topical application ofthe agonist to the hamster cheek pouch (32) . The mechanism of the LTB4-stimulated neutrophil adherence to endothelial cell monolayers in vitro is a selective effect on the endothelial cells to increase their adherence capacity for neutrophils (99) . This finding is consistent with the selective adherence of neutrophils in vivo to venules within the area of tissue injury (100).
Pharmacotherapeutic intervention. The rationale for seeking pharmacotherapeutic agents to limit leukotriene biosynthesis and/or end-organ effects is based upon the potent proinflammatory actions of these compounds in pharmacologic studies ofnormal humans, the demonstrated in vitro capacities ofcertain human cells and tissues to generate leukotrienes in response to selected agonists (Table I) Inhibitors for several of the biosynthetic enzymes in the 5-lipoxygenase pathway (Fig. 1 ) have been synthesized and tested in both cell-free and cellular systems. Historically, the first recognized inhibitor ofthis cascade was diethylcarbamazine, which prevented the generation of SRS-A in rat peritoneal cavities prepared with hyperimmune serum and challenged with specific antigen (108, 109) , and in monkey and human lung fragments activated by IgE-dependent mechanisms (110, 111) . More recently, diethylcarbamazine was shown to act as an inhibitor of the conversion of 5-HPETE to LTA4 by ionophore-activated murine mastocytoma cells (112) and by IgE-sensitized bone marrow-derived murine mast cells activated by specific antigens ( 113) . The 5,8,11, 14-tetraethylenic derivative ofarachidonic acid and a variety of antioxidants (e.g., BW755c and nordihydroguaiaretic acid) have been shown to have inhibitory activities for the 5-lipoxygenase as well as other monolipoxygenases and cyclooxygenase, and are not specific (101) . In contrast, 5,6-dehydro-arachidonic acid has been shown to be a specific inhibitor of cell-free 5-lipoxygenase prepared from RBL-l cells (1 14, 115) and to prevent, in a dose-related manner, the antigeninduced generation of 5S-hydroxy-6-trans-8, 11, 14-cis-eicosatetraenoic acid (5-HETE), LTC4, and LTB4 from murine bone marrow-derived mast cells under conditions that do not influence secretion of granule constituents (113) . That secretion is not necessarily linked to 5-lipoxygenase pathway function, suggests that their apparent dependence in other studies (1 16) may have been due to the use of nonspecific inhibitors. The conversion of LTA4 to LTC4 by glutathione-S-transferase is inhibited by a prostacycline analogue, 6,9-deepoxy-6,9-phenylimino-A6'8-prostaglandin I, (U-60,257), in ionophore-activated rat mononuclear cells (1 17) , and this effect is selective in murine bone marrow-derived mast cells activated by an IgE-dependent mechanism (1 13).
A second mechanism for exerting control over the 5-lipoxygenase pathway products is by providing alternative substrates in the membrane phospholipids, thereby yielding products with less total proinflammatory activity. Eicosapentaenoic acid, incorporated into membrane lipids of human platelets and rat synovial cells, is a poor substrate for the cyclooxygenase pathway and may, in addition, inhibit the generation of cyclooxygenase products from arachidonic acid (118, 119). Murine mastocytoma cells, grown in the peritoneal cavities of mice fed an eicosa-pentaenoic acid-enriched diet and then stimulated in vitro with calcium ionophore, generated LTB4 and LTB5 (5,12-dihydroxy-6,8,10,14,17-eicosapentaenoic acid), in preference to LTC4 and LTC5 (5-hydroxy-6-S-glutathionyl-7,9-trans-I 1,14,1 7-cis-eicosapentaenoic acid) (120). The 5-lipoxygenase products generated by immune complexes in peritoneal cavities of rats fed an eicosapentaenoic acid (fish fatty acid)-enriched diet also preferentially included LTB5/LTB4 relative to LTC5/LTC4 (121) . Additionally, although LTC5 has comparable spasmogenic activity to LTC4 in contracting the guinea pig ileum and pulmonary parenchymal strips (121), LTB5 is one-tenth as potent and is a partial agonist relative to LTB4 as a chemotactic or aggregating agent for human PMN (122) .
A third approach involves antagonism ofleukotrienes at the receptor level. The capacity of FPL55712 to inhibit antigeninduced anaphylaxis in monkeys (123) and to abrogate the cardiovascular and renal abnormalities resulting from intravenous administration of LTC4 to rats (36) exemplifies this approach. The agent is generally active only at relatively high concentrations and presumably acts only at LT-RI; it can thus be considered as a feasibility prototype for design of new compounds.
Concluding comments. The oxidative metabolism of arachidonic acid in response to cell perturbation, physiologic or pathobiologic, provides the microenvironment with a unique array of membrane-derived lipid mediators of remarkable potency. The only points of regulation that are well recognized at present relate to the selective biochemical machinery of each cell type and the distribution of class-and subclass-specific leukotriene receptors among and within target cells. It is likely, however, that another major control point will be recognized when receptor-specific stimuli are used to activate cells for leukotriene biosynthesis. For example, in adherent human monocytes, phagocytosis ofunopsonized zymosan releases both LTC4 and LTB4, whereas comparable numbers of monocytes that are ingesting particles via an Fc-IgG receptor generate one-tenth the quantity ofeach leukotriene (55) . Whether receptor-mediated regulation of oxidative metabolism of arachidonic acid relates to the distribution and action of membrane phospholipases and lipases or to presentation of phospholipid substrate(s) or both is not known. It is necessary to restudy each responding cell type, using discrete stimuli for transmembrane activation, rather than the nonspecific agonist, calcium ionophore A23187, and additionally to carry out simultaneous assessment of product bioconversion and catabolism. Additionally, the specificities of sulfidopeptide leukotriene receptors on vascular endothelium and smooth muscle, as well as nonvascular smooth muscle, need to be delineated since it seems logical that the blood vessels, rather than the circulating leukocytes, are the critical targets early in inflammation (99, 100) . Further characterization of the class-and subclass-selective leukotriene receptors and their cellular and subcellular distribution (27, 30) should lead to clarification of the differences in functions mediated by each and to biochemical assessment of the mechanisms that mediate postreceptor functional responses. Finally, it will be crucial to develop new pharmacological agents, both to assess putative relationships between the 5-lipoxygenase pathway and cellular functions, such as secretion, and to provide clinical probes that may clarify the true roles of the leukotrienes in health and disease.
